Toragen launches Phase 1 trial of TGN-S11 in HPV-associated cancer
Toragen, a San Diego-based clinical-stage biotechnology company, has launched a Phase 1 clinical trial to evaluate its initial drug candidate, TGN-S11, targeting cancers instigated by viruses. This advancement could potentially revolutionize the treatment of Human Papillomavirus (HPV) related cancers. HPV is believed to dwell within cells, remaining unnoticed by the immune system, which can eventually […]